Search Results

LumiThera Inc. announced an update on the regulatory status of the Valeda® Light Delivery System.

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda ® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD).

LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years.

LumiThera Inc., a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease, announced the purchase of MacuLogix assets by its wholly owned subsidiary.

LumiThera Inc. today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda ® Light Delivery System.

LumiThera Inc. is proud to announce that the AdaptDx Pro® has been recognized as one of Fast Company’s 2022 Innovation and Design Award honorees.

LumiThera Inc., a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease, announced the completion of a debt financing with Leste Clearway and Serengeti Asset Management.

LumiThera Inc today announced the completion of its acquisition of Diopsys, Inc., a leader in modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders.

LumiThera Inc announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with Photobiomodulation using the Valeda® Light Delivery System.